Analysts’ views on Johnson & Johnson
Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.
Over the last month, JNJ stock has generated increased interest due to some key product approvals and trial data announcements. However, it continues to be embroiled in some significant litigation battles. Let’s look at analysts’ recommendations for JNJ stock for the next 12 months.
Recommendations and target prices
According to a September 13 Reuters survey of analysts covering JNJ stock, ~52% of them are recommending a “buy” or “strong buy” for the stock. Nine analysts (or ~43%) have given it a “hold.” Only one analyst has recommended a “sell.” Their consensus target price for JNJ for the next 12 months is $143.35, which implies a ~2.9% increase based on its closing price of $139.36 on September 12.
As of September 13, analysts’ average target prices for peers Pfizer (PFE), Mylan (MYL), and GlaxoSmithKline (GSK) are $42.20, $46.84, and $43.06, respectively, implying -0.50%, 24.3%, and 9.4% returns, respectively, over the next 12 months.
In July, Goldman Sachs upgraded its recommendation on JNJ stock from “sell” to “neutral.”
In the next part of this series, let’s look at JNJ’s recent stock performance.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!